ALLIANCE PHARMA PLC

Share Issue/Capital Change • Jun 21, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7891I

Alliance Pharma PLC

21 June 2017

For immediate release	21 June 2017

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Application for block admission

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that it has today applied for a block admission for a further 25,000,000 ordinary shares of 1p each in the Company ("Ordinary Shares") to be admitted to trading on AIM (the "Block Admission"). The Block Admission will be used to facilitate the admission of shares to trading following the exercise of options granted under the following employee share schemes:

·  The Alliance Pharma plc Approved Share Option Plan 2005 (up to 2,248,922 shares);

·  The Alliance Pharma plc Share Option Plan 2006 (up to 19,461,225 shares); and

·  The Alliance Pharma plc Company Share Option Plan 2015 (up to 3,289,853 shares).

It is expected that the Block Admission will become effective in the Ordinary Shares on 28 June 2017.

The Company will make six-monthly announcements of the utilisation of the Block Admission, in line with its obligations under AIM Rule 29.

New Ordinary Shares issued following option exercises and admitted to trading under the Block Admission will rank pari passu in all respects with the existing Ordinary Shares.

At the time of this application, Alliance has 474,307,589 Ordinary Shares in issue.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer
Rob Bellhouse, Company Secretary
www.alliancepharma.co.uk
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Sophie Cowles
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black / Toby Adcock

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ALSFBMJTMBATBMR